Premium
Proceedings From FDA/A.S.P.E.N. Public Workshop
Author(s) -
Teitelbaum Daniel H.,
Guenter Peggi,
Griebel Donna,
Abrams Steven A.,
Bark Staffan,
Baker Mary,
Berry Karyn L.,
Bistrian Bruce R.,
Brenna J. Thomas,
Bonnot Denis,
Carpentier Yvon A.,
Deckelbaum Richard J.,
Hise Mary,
Koletzko Berthold,
Mirtallo Jay M.,
Mulberg Andrew E.,
O'Reilly Randall C.,
Shaffer Jonathan,
Kleist Elke,
Zaloga Gary P.,
Ziegler Thomas R.
Publication year - 2015
Publication title -
journal of parenteral and enteral nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.935
H-Index - 98
eISSN - 1941-2444
pISSN - 0148-6071
DOI - 10.1177/0148607114560825
Subject(s) - parenteral nutrition , food and drug administration , fat emulsion , medicine , enteral administration , intensive care medicine , drug development , gerontology , pharmacology , drug
The development of intravenous fat emulsion (IVFE) is the culmination of physiological, biochemical, nutritional, and medical scientific advancements. IVFEs have the ability to deliver critical nutritional substrates to the patient. Recent literature purports that they may also play roles in modulation of immune functionality and pulmonary physiology, but data supporting these potential benefits are limited. While soybean‐based IVFEs have comprised the dominant fat in U.S. markets, a number of other novel IVFEs may prove to optimize the care of children and adults in both hospitalized and home settings. The October 2013 U.S. Food and Drug Administration (FDA)/American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Public Workshop brought together scientists, researchers, and clinical experts to present updated clinical perspectives of IVFEs, including historical development, current state of usage throughout the world, and considerations for the regulatory approval of new IVFEs in the United States.